arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Bioventus Inc.

BVS
$14.12 ▲ +0.14 (+1.04%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
25 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
57
Health
Fair
Bearish
auto_awesome

Analytical Summary

Bioventus Inc. faces fundamental challenges with weakness in Debt to Equity. The fundamentals warrant careful consideration of downside risks.

Market Cap $950.2M
Dividend Yield
Revenue Growth 6.6%
Op. Margin 6.4%
ROIC 1.7%
FCF / Share $0.12
Trailing P/E 282.4x
Price / Book 5.0x
FCF Yield 0.9%
Debt / Equity 1.34
info Valuation on last close. End-of-day price, Aug 7, 2026.

25-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$132.09M
↑ +6.6%
Net Income Profit after all expenses
$3.11M
↓ -78.9%
Operating Margin Operating profit as % of sales
6.4%
↓ -48.4% 55th
FCF / Share Free cash flow per share
$0.12
↓ -71.9%
Long-Term Debt Long-term obligations
$253.33M
↓ -9.2%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)

Health Breakdown

Profitability
56
Returns
75
Financial Health
17
Cash Quality
92

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 25 quarters